Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Liver transplantation for hilar cholangiocarcinoma: A systematic review.

Publication ,  Journal Article
Machairas, N; Kostakis, ID; Tsilimigras, DI; Prodromidou, A; Moris, D
Published in: Transplantation reviews (Orlando, Fla.)
January 2020

Patients with hilar cholangiocarcinoma (hCCA) have advanced disease at presentation and therefore curative treatment options are limited. Liver transplantation (LT), in the case of unresectable disease, is theoretically an attractive option, as it offers the maximum resection margin and at the same time removes the underlying parenchymal liver disease. In the past years a number of studies have aimed to evaluate to potential beneficial role of neo adjuvant therapy followed by LT for treating patients with unresectable hCCA. The objective of our systematic review was to collect and evaluate long-term outcomes of patients with hCCA undergoing LT. A systematic search of 4 electronic databases (Medline, Scopus, Google Scholar and ClinicalTrails.gov databases) was performed for articles published between January 2000 and May 2019. A total of 13 studies with 698 patients were finally included in the present systematic review. A proportion of 74.4% of patients received combination of chemotherapy and radiation as a part of neoadjuvant therapy. One-, 3- and 5-year overall survival rates ranged greatly among the included studies from 58% to 92%, 31% to 80% and 20% to 74%, respectively. Recurrence rates ranged from 16% to 61%, whilst perioperative mortality ranged from 0% to 25.5%. LT could provide acceptable long-term outcomes in the setting of neoadjuvant chemoradiation and strict patient selection criteria. Taking into account organ shortage, combined with the lack of level I evidence, more prospective randomized trials are needed in order to establish certain indications, rigorous criteria and standardized protocols for LT in hCCA and provide the maximal potential benefits for these patients.

Duke Scholars

Published In

Transplantation reviews (Orlando, Fla.)

DOI

EISSN

1557-9816

ISSN

0955-470X

Publication Date

January 2020

Volume

34

Issue

1

Start / End Page

100516

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Surgery
  • Patient Selection
  • Neoadjuvant Therapy
  • Liver Transplantation
  • Klatskin Tumor
  • Humans
  • Evidence-Based Medicine
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Machairas, N., Kostakis, I. D., Tsilimigras, D. I., Prodromidou, A., & Moris, D. (2020). Liver transplantation for hilar cholangiocarcinoma: A systematic review. Transplantation Reviews (Orlando, Fla.), 34(1), 100516. https://doi.org/10.1016/j.trre.2019.100516
Machairas, Nikolaos, Ioannis D. Kostakis, Diamantis I. Tsilimigras, Anastasia Prodromidou, and Dimitrios Moris. “Liver transplantation for hilar cholangiocarcinoma: A systematic review.Transplantation Reviews (Orlando, Fla.) 34, no. 1 (January 2020): 100516. https://doi.org/10.1016/j.trre.2019.100516.
Machairas N, Kostakis ID, Tsilimigras DI, Prodromidou A, Moris D. Liver transplantation for hilar cholangiocarcinoma: A systematic review. Transplantation reviews (Orlando, Fla). 2020 Jan;34(1):100516.
Machairas, Nikolaos, et al. “Liver transplantation for hilar cholangiocarcinoma: A systematic review.Transplantation Reviews (Orlando, Fla.), vol. 34, no. 1, Jan. 2020, p. 100516. Epmc, doi:10.1016/j.trre.2019.100516.
Machairas N, Kostakis ID, Tsilimigras DI, Prodromidou A, Moris D. Liver transplantation for hilar cholangiocarcinoma: A systematic review. Transplantation reviews (Orlando, Fla). 2020 Jan;34(1):100516.
Journal cover image

Published In

Transplantation reviews (Orlando, Fla.)

DOI

EISSN

1557-9816

ISSN

0955-470X

Publication Date

January 2020

Volume

34

Issue

1

Start / End Page

100516

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Surgery
  • Patient Selection
  • Neoadjuvant Therapy
  • Liver Transplantation
  • Klatskin Tumor
  • Humans
  • Evidence-Based Medicine
  • Combined Modality Therapy